HCG (Fertility) vs Letrozole
A side-by-side research comparison of HCG (Fertility) and Letrozole across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | HCG (Fertility) | Letrozole |
|---|---|---|
| Full name | HCG for Ovulation Trigger (Pregnyl/Ovidrel) | Letrozole (Femara) |
| Category | Fertility | Fertility |
| Status | FDA Approved | FDA Approved (off-label fertility) |
| Mechanism | Binds LH/CG receptors on the dominant follicle, triggering resumption of meiosis in the oocyte, luteinization of granulosa cells, and follicular rupture (ovulation) within 36-40 hours of administration. | Reversibly inhibits aromatase (CYP19A1), blocking conversion of androgens to estrogens. In women, transient estrogen reduction triggers hypothalamic GnRH release for FSH surge. In men, reduces estradiol while maintaining testosterone. |
| Molecular weight | ~36,700 Da | 285.30 Da |
| Half-life | ~33 hours | ~2 days |
| Bioavailability | ~100% (subcutaneous/intramuscular) | ~100% oral |
| Typical dose | 5000-10,000 IU (Pregnyl) or 250 mcg (Ovidrel) | 2.5-7.5 mg (women, day 3-7); 0.5-2.5 mg (men, 2-3x/week) |
| Frequency | Single injection timed to follicle maturity | Cyclic (women) or 2-3x weekly (men) |
| Route | Subcutaneous or intramuscular | Oral tablet |
HCG (Fertility) reported benefits
- Precise ovulation timing
- Final oocyte maturation
- Corpus luteum support
- IUI/IVF timing coordination
- Luteal phase support
Letrozole reported benefits
- Ovulation induction (PCOS)
- Higher live birth rates than clomiphene
- No anti-estrogenic endometrial thinning
- Estradiol control in men
- Lower multiple pregnancy rate
Related comparisons
Research and educational reference only. Not medical advice.